Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Float Short %

40.56

Margin Of Safety %

Put/Call OI Ratio

0.36

EPS Next Q Diff

-0.07

EPS Last/This Y

1.28

EPS This/Next Y

0.36

Price

9.03

Target Price

22.21

Analyst Recom

2.22

Performance Q

-22.04

Relative Volume

0.43

Beta

2.06

Ticker: NTLA




20 items of 1

DateSymbolLatestP/C OIP/C VolTotal OI
2025-11-13NTLA8.660.400.79163346
2025-11-14NTLA8.680.380.55162882
2025-11-17NTLA8.480.381.16163764
2025-11-18NTLA8.470.370.49163680
2025-11-19NTLA8.250.350.72160245
2025-11-20NTLA8.050.330.27159174
2025-11-21NTLA8.220.320.14158236
2025-11-24NTLA8.350.410.11112731
2025-11-25NTLA8.550.410.09114438
2025-11-26NTLA8.530.400.30114888
2025-12-01NTLA8.390.390.37117120
2025-12-02NTLA8.10.390.24117495
2025-12-03NTLA9.020.380.06118557
2025-12-04NTLA9.70.380.23119965
2025-12-05NTLA9.60.380.20121512
2025-12-08NTLA9.450.370.19122217
2025-12-09NTLA9.310.370.44122347
2025-12-10NTLA9.390.370.18123233
2025-12-11NTLA9.550.370.42123955
2025-12-12NTLA9.020.360.12126309
DateSymbolLatestP/C OIP/C VolTotal OI
20 items Current Page1 of 1




20 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-11-13NTLA8.6526.668.3-3.97
2025-11-14NTLA8.6922.3-1.8-3.97
2025-11-17NTLA8.4823.421.5-3.97
2025-11-18NTLA8.4723.40.9-3.97
2025-11-19NTLA8.2423.422.9-3.97
2025-11-20NTLA8.0423.421.2-3.97
2025-11-21NTLA8.2224.0-18.6-3.97
2025-11-24NTLA8.3524.0-13.2-3.97
2025-11-25NTLA8.5524.0-19.5-3.97
2025-11-26NTLA8.5224.03.1-3.97
2025-12-01NTLA8.4324.350.4-3.97
2025-12-02NTLA8.1024.332.2-3.97
2025-12-03NTLA9.0624.3-97.7-3.97
2025-12-04NTLA9.7524.3-59.3-3.97
2025-12-05NTLA9.6124.310.6-3.97
2025-12-08NTLA9.4424.3- -3.97
2025-12-09NTLA9.3024.314.8-3.97
2025-12-10NTLA9.3924.3-7.0-3.97
2025-12-11NTLA9.5624.3-15.0-3.97
2025-12-12NTLA9.0324.342.1-3.97
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
20 items Current Page1 of 1




20 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-11-13NTLA1.36-1.8635.66
2025-11-14NTLA1.36-1.8635.56
2025-11-17NTLA1.448.4935.56
2025-11-18NTLA1.448.4935.56
2025-11-19NTLA1.448.4935.56
2025-11-20NTLA1.448.4935.56
2025-11-21NTLA1.448.4935.56
2025-11-24NTLA1.445.0835.56
2025-11-25NTLA1.445.0835.56
2025-11-26NTLA1.445.0836.61
2025-12-01NTLA1.444.9836.61
2025-12-02NTLA1.444.9836.61
2025-12-03NTLA1.444.9836.61
2025-12-04NTLA1.444.9836.61
2025-12-05NTLA1.444.9836.61
2025-12-08NTLA1.444.9636.61
2025-12-09NTLA1.444.9636.61
2025-12-10NTLA1.444.9640.56
2025-12-11NTLA1.444.9640.56
2025-12-12NTLA-0.074.9640.56
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
20 items Current Page1 of 1

[stock_market_widget type="chart" template="candlestick" assets="NTLA" range="1y" interval="1d" price_field="close" heading="{symbol}" candle_border_width="1" candle_bullish_background_color="#21BA45" candle_bearish_background_color="#DB2828" candle_bullish_border_color="#21BA45" candle_bearish_border_color="#DB2828" axes_color="#000000" tooltip_text_color="#262626" tooltip_background_color="#ffffff" range_selector="true" volume_enabled="true" axes_enabled="true" tooltip_enabled="false" zoom_enabled="true" save_image_enabled="true" volume_bar_fill_color="#5679FF" api="yahoo-finance"]

Last Quarter Act. EPS

-0.92

Avg. EPS Est. Current Quarter

-0.96

Avg. EPS Est. Next Quarter

-0.99

Insider Transactions

-0.07

Institutional Transactions

4.96

Beta

2.06

Average Sales Estimate Current Quarter

12

Average Sales Estimate Next Quarter

10

Fair Value

Quality Score

16

Growth Score

32

Sentiment Score

23

Actual DrawDown %

95.6

Max Drawdown 5-Year %

-96.4

Target Price

22.21

P/E

Forward P/E

PEG

P/S

18.16

P/B

1.4

P/Free Cash Flow

EPS

-4.27

Average EPS Est. Cur. Y​

-3.97

EPS Next Y. (Est.)

-3.6

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-774.94

Relative Volume

0.43

Return on Equity vs Sector %

-86.5

Return on Equity vs Industry %

-71.5

EPS 1 7Days Diff

EPS 1 30Days Diff

0.15

EBIT Estimation

42.1
[stock_market_widget type=”table-options” template=”gradient” color=”#5679FF” assets=”NTLA” fields=”contract_symbol,type,strike,price,change_pct,implied_volatility,change_abs,open_interest,volume,in_the_money,bid,ask” pagination=”true” rows_per_page=”21″ sort_direction=”asc” alignment=”left” search=”true” sort_field=”strike” api=”yahoo-finance”]
[stock_market_widget type=”chart-options” template=”basic” color=”#5679FF” assets=”NTLA” options_type=”calls” x_axis_field=”strike” y_axis_field=”price” axes=”true” cursor=”true” display_currency_symbol=”true” api=”yf”]
[stock_market_widget type=”chart-options” template=”basic” color=”#5679FF” assets=”NTLA” options_type=”puts” x_axis_field=”strike” y_axis_field=”price” axes=”true” cursor=”true” display_currency_symbol=”true” api=”yf”]
[stock_market_widget type=”chart-options” template=”basic” color=”#5679FF” assets=”NTLA” options_type=”calls” x_axis_field=”strike” y_axis_field=”implied_volatility” axes=”true” cursor=”true” display_currency_symbol=”true” api=”yf”]
[stock_market_widget type=”chart-options” template=”basic” color=”#5679FF” assets=”NTLA” options_type=”puts” x_axis_field=”strike” y_axis_field=”implied_volatility” axes=”true” cursor=”true” display_currency_symbol=”true” api=”yf”]
[stock_market_widget type=”chart-options” template=”basic” color=”#5679FF” assets=”NTLA” options_type=”calls” x_axis_field=”strike” y_axis_field=”volume” axes=”true” cursor=”true” display_currency_symbol=”true” api=”yf”]
[stock_market_widget type=”chart-options” template=”basic” color=”#5679FF” assets=”NTLA” options_type=”puts” x_axis_field=”strike” y_axis_field=”volume” axes=”true” cursor=”true” display_currency_symbol=”true” api=”yf”]
Intellia Therapeutics, Inc.
Sector: Healthcare
Industry: Biotechnology
Employees: 403
Intellia Therapeutics, Inc., a clinical-stage gene editing company, focuses on the development of curative genome editing treatments. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 that is in Phase 1/2 study for the treatment of hereditary angioedema. It also focusses on the research of proprietary programs focused on developing engineered cell therapies to treat various cancers and autoimmune diseases. The company has license and collaboration agreement with AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies; Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of various of B cell-mediated autoimmune diseases; ONK Therapeutics, Ltd. for the development of engineered NK cell therapies to cure patients with cancer; and ReCode Therapeutics, Inc. to develop novel genomic medicines for the treatment of cystic fibrosis. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
stock quote shares NTLA – Intellia Therapeutics, Inc. Stock Price stock today
news today NTLA – Intellia Therapeutics, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch NTLA – Intellia Therapeutics, Inc. yahoo finance google finance
stock history NTLA – Intellia Therapeutics, Inc. invest stock market
stock prices NTLA premarket after hours
ticker NTLA fair value insiders trading